SAN DIEGO – June 21, 2005 – Verus Pharmaceuticals, Inc., a pediatric-oriented company dedicated to identifying, developing and delivering solutions to address the unmet medical needs of children and those who care for them, today announced that it has been named to FierceBiotech's annual Fierce 15 list. This distinction honors Verus as one of the top 15 emerging biotech companies for 2005. FierceBiotech, an internationally recognized email newsletter covering the biotechnology and pharmaceutical markets, evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position.
"If past successes are any indication, don't expect Verus to waste any time making its mark. This management team appears to know exactly what it's doing," says John D. Carroll, of FierceBiotech. "Like the other swiftly developing companies on this year's Fierce 15 list, we'll be watching Verus closely in the years ahead."
"FierceBiotech is recognized for its advanced understanding of biotech companies and the industry as a whole," said Robert W. Keith, President and Chief Operating Officer of Verus. "Being selected as a member of the Fierce 15 is an honor that highlights Verus' potential to make a significant impact in the industry and in the lives of children."
The Fierce 15 celebrates the spirit of being "fierce" - championing innovation and creativity, even in the face of intense competition. The list of Fierce 15 companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at http://www.fiercebiotech.com.
About FierceBiotech
FierceBiotech, an internationally recognized email newsletter for the biotech industry, provides more than 35,000 executives a must-read briefing on the day's top stories in the biotech and pharmaceutical industries. Visit http://www.fiercebiotech.com for additional information.
About Verus
Verus Pharmaceuticals is dedicated to improving the lives of children and those who care for them. Verus is building a portfolio of products for the unmet medical needs of children through acquisitions and alliances, with an initial focus on the treatment of asthma, allergies, and related diseases and conditions. Verus is differentiated by its pediatric orientation and its strong financial position and experienced management team, which allows the company to capitalize on an extensive network to build its product portfolio and pursue complementary transactions. The company's rigorous, disciplined approach to strategic decision-making and core competencies in development and commercialization is expected to provide significant value to its partners. More information about Verus is available on the company's website at www.veruspharm.com.
Forward-Looking Statements
Verus Pharmaceuticals cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Verus that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Verus' business including, without limitation, statements about: its ability to identify appropriate acquisition, licensing, or co-development and/or promotion candidates in the future or be able to take advantage of the opportunities it identifies; difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products; unexpected performance or side effects of its products that could delay or prevent development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and Verus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
|
